Friday, July 10, 2026

pharma · Obesity, Overweight · Type 2 Diabetes

Eli Lilly and

Eli Lilly Co is a pharma organization headquartered in EU. Primary therapeutic focus areas include Obesity, Overweight, Type 2 Diabetes, Ulcerative Colitis, Type 2 Diabetes Mellitus, Breast Cancer. NovaPharmaNews links 1

Lilly Corporate Center, Indianapolis, Indiana 46285, US HQ
1876 Founded
55,860 Employees
EMA registrant Type
Company details
Status
Public
HQ
Lilly Corporate Center, Indianapolis, Indiana 46285, US
Founded
1876
Employees
55,860
Programs
107
Drugs
99
Patents
0
Clinical program

J3R-MC-YDAH

Phase 1 · other · Participants with Mild, Moderate, or Severe Hepatic Impairment and Participants with Normal Hepatic Function

J3R-MC-YDAH for Participants with Mild, Moderate, or Severe Hepatic Impairment and Participants with Normal Hepatic Function is a Phase 1 program (other) at Eli Lilly Co. with 1 ClinicalTrials.gov record(s).

Internal code J3R-MC-YDAH

Full intelligence profile for this program is being prepared.

At a glance

Sponsor
Eli Lilly Co.
Phase
Phase 1
Modality
other
Indication
Participants with Mild, Moderate, or Severe Hepatic Impairment and Participants with Normal Hepatic Function
Status
active
Trials
1